Montelukast in the treatment of HIV associated immune reconstitution disease

Sexually Transmitted Infections

Volumn 82, Issue 6, 2006, Pages 513-514

  Hardwick, Christine ^a   White, D ^a   Morris, E ^b   Monteiro, E F ^b   Breen, R A ^c   Lipman, M ^c  

^a BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^b LEEDS GENERAL INFIRMARY   (United Kingdom)

^c ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; MONTELUKAST; STEROID;

ADULT; ANAMNESIS; ARTICLE; CASE REPORT; CLINICAL FEATURE; DISEASE ASSOCIATION; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; LONG TERM CARE; LUNG TUBERCULOSIS; LYMPH NODE BIOPSY; MALE; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; SYPHILIS;

ACETATES; ADJUVANTS, IMMUNOLOGIC; FEMALE; HIV INFECTIONS; HUMANS; IMMUNE SYSTEM DISEASES; MALE; QUINOLINES;

EID: 33845886652     PISSN: 13684973     EISSN: None     Source Type: Journal    
DOI: 10.1136/sti.2005.017863     Document Type: Article

References (6)

1. Lawn SD, Bekker L, Miller RF. Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect Dis 2005;5:361-73.
2. Bourgarit A, Carcelain G, Martinez V, et al. Explosion of tuberculin-specific Th1 responses induces immune restoration syndrome in tuberculosis and HIV co-infected patients. AIDS 2006;20:F1-F7.
3. Peters-Golden M, Canetti C, Mancuso P, et al. Leukotrienes: underappreciated mediators of innate immune responses. J Immunol 2004;173:589-94.
4. Coffey MJ, Phare SM, George S, et al. Granulocyte colony-stimulating factor administration to HIV infected subjects augments reduced leukotriene synthesis and anticryptococcal activity in neutrophils. J Clin Invest 1998;102:663-70.
5. Salvi SS, Krishna MT, Sampson AP, et al. The anti-inflammatory effects of leukotriene-modifying drugs and their use in asthma. Chest 2001;119:1533-46.
6. MSD. Summary of product characteristics for montelukast.